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Abstract  71 
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity 72 
pandemic but at present there are no approved therapies. Here, we aimed to revert high-fat diet (HFD)-induced 73 
obesity and NAFLD in mice by enhancing liver fatty acid oxidation (FAO). Moreover, we searched for 74 
potential new lipid biomarkers for monitoring liver steatosis in humans. We used adeno-associated virus (AAV) 75 
to deliver a permanently active mutant form of human carnitine palmitoyltransferase 1A (hCPT1AM), the key 76 
enzyme in FAO, in the liver of a mouse model of HFD-induced obesity and NAFLD. Expression of hCPT1AM 77 
enhanced hepatic FAO and autophagy, reduced liver steatosis and improved glucose homeostasis. Lipidomic 78 
analysis in mice and humans before and after therapeutic interventions, such as hepatic AAV9-hCPT1AM 79 
administration and RYGB surgery respectively, led to the identification of specific triacylglyceride (TAG) 80 
specie (C50:1) as a potential biomarker to monitor NAFFLD disease. To sum up, here we show for the first 81 
time that liver hCPT1AM gene therapy in a mouse model of established obesity, diabetes and NAFLD can 82 
reduce HFD-induced derangements. Moreover, our study highlights TAG (C50:1) as a potential non-invasive 83 
biomarker that might be useful to monitor NAFLD in mice and humans. 84 
Keywords: AAV, gene therapy, fatty-acid oxidation, CPT1A, lipid biomarker, hepatic steatosis, obesity 85 
86 
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1. Introduction 87 
Despite enormous efforts by health care providers and the research community, obesity rates continue to rise. 88 
Unfortunately, safe, long-term efficient treatments are currently unavailable. Of great concern is the parallel 89 
increase in the prevalence of obesity-associated pathological conditions such as insulin resistance, type 2 90 
diabetes (T2D), nonalcoholic fatty liver disease (NAFLD), cardiovascular disease and cancer. Hence, it is vital 91 
to develop novel therapeutic strategies to combat this epidemic. 92 
One of the main causes of obesity is the modern lifestyle, which is characterized by excessive calorie intake and 93 
insufficient physical activity. The liver plays an essential role in regulating whole-body energy balance and 94 
lipid/glucose homeostasis. In conditions associated with prolonged excess energy intake, the liver can store 95 
significant quantities of lipids, which eventually leads to steatosis. Liver steatosis can cause hepatic 96 
inflammation and progress to steatohepatitis (NASH) (1), which predisposes to hepatic injury and cancer. The 97 
design of new therapeutic strategies to enhance fat burning in liver may alleviate these obesity-related 98 
disorders. 99 
Mitochondrial long-chain fatty acid -oxidation (FAO) is regulated by carnitine palmitoyltransferase 1 (CPT1). 100 
This enzyme is physiologically inhibited by malonyl-CoA, a glucose-derived metabolite that is an intermediate 101 
in the de novo synthesis of fatty acids (FA). Increased glucose metabolism raises levels of malonyl-CoA, which 102 
inhibits CPT1 and blocks FAO, resulting in lipid partitioning and storage. A significant number of studies in 103 
rodents have tried to indirectly promote FAO to reduce systemic obesity and prevent the development of 104 
obesity-associated metabolic disorders. These studies targeted the regulation of enzymes and transcription 105 
factors involved in FA metabolism, such as acetyl-CoA carboxylase (ACC) (2), malonyl-CoA decarboxylase 106 
(MCD) (3), uncoupling protein 1 (UCP1) (4), AMP-activated protein kinase (AMPK) (5), peroxisome 107 
proliferator-activated receptor (PPAR) (6), and long chain acyl-CoA dehydrogenase (VLCAD) (7). Studies that 108 
increased short-term CPT1A activity in liver demonstrated a decrease in hepatic triglyceride (TAG) content  109 
(8), but did not report any improvement in insulin sensitivity. Furthermore, we and others have shown that a 110 
long-term increase in CPT1A and a mutated isoform that is insensitive to malonyl-CoA (CPT1AM) (9) 111 
prevented steatosis and the development of obesity in mice fed a high-fat diet (HFD)  (10, 11). Still, these 112 
studies could not revert the HFD-induced derangements in an established model of obesity. 113 
The aim of the present study was to determine whether AAV-mediated long-term activation of hepatic FAO 114 
could be a successful strategy to revert an already established obesity with associated hyperglycemia and 115 
NAFLD in mice. We focused on three novel strategies: 1) use of the AAV9 serotype, which is the most 116 
effective AAV in gene therapy at targeting liver; 2) use of a mouse model with established obesity, type 2 117 
diabetes and NAFLD; and 3) use of the human isoform of CPT1AM (hCPT1AM), with the prospect of future 118 
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clinical therapeutic applications. Our results show that enhanced hepatic FAO through hCPT1AM-mediated 119 
gene therapy reduces diet-induced weight gain, and hepatic steatosis and improves hepatic insulin signaling in 120 
obese mice. Mechanistically, hCPT1AM-expressing mice showed enhanced autophagy, ketogenesis and 121 
oxidative phosphorylation in the liver. Importantly, hCPT1AM expression also changes the hepatic lipidomic 122 
profile. One of the altered lipid species, C50:1 triacylglyceride, was concomitantly lower in the serum of human 123 
patients with obesity and NAFLD after bariatric surgery. Thus, we identified a potential biomarker to monitor 124 
the progression of hepatic steatosis in humans. 125 
126 
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2. Materials and Methods 127 
2.1. Human study cohort and biological analysis 128 
Serum samples were obtained from obese patients (BMI ≥ 30 kg/m2 and body fat percentage [BF] ≥ 35% for 129 
women and ≥ 25% for men) before and six months after Roux-en-Y gastric bypass (RYGB) (n=15) and from 130 
healthy lean volunteers (n=15) at the Clínica Universidad de Navarra. Inclusion criteria included a complete 131 
diagnosis: physical examination, laboratory investigation, ultrasound echography and a liver biopsy consistent 132 
with the diagnosis of nonalcoholic fatty liver disease (NAFLD), according to Brunt criteria  (12). Exclusion 133 
criteria were: i) excess alcohol consumption (≥ 20 g for women and ≥ 30 g for men); ii) the presence of 134 
hepatitis B virus surface antigen or hepatitis C virus antibodies in the absence of a history of vaccination; iii) 135 
use of drugs linked to NAFLD, including amiodarone, valproate, tamoxifen, methotrexate, corticosteroids or 136 
antiretrovirals; iv) evidence of other specific liver diseases, such as autoimmune liver disease, 137 
haemochromatosis, Wilson’s disease or α-1-antitrypsin deficiency. Patients with type 2 diabetes (T2D) were 138 
not on any antidiabetic treatment before or during the study. Obese patients with T2D did not have a long 139 
history of diabetes (less than 2–3 years or even de novo diagnosis as evidenced from their anamnesis and 140 
biochemical determinations). Glucose, uric acid, ALT, AST, alkaline phosphatase, and γ-glutamyltransferase 141 
(γ-GT) were measured by enzymatic tests (Hitachi Modular P800, Roche, Basel, Switzerland). Total 142 
cholesterol, HDL-cholesterol, LDL-cholesterol, and triacylglycerol concentrations (Roche) were calculated as 143 
previously described  (13). High sensitivity C-reactive protein (CRP) was measured using the Tina-quant® 144 
CRP (Latex) ultrasensitive assay (Roche). Insulin was measured by an enzyme-amplified chemiluminescence 145 
assay (IMMULITE; Diagnostics Products Corp., Los Angeles, CA, USA). Intra- and inter-assay coefficients of 146 
variation were 4.2 and 5.7%, respectively. Insulin resistance and sensitivity were calculated using the 147 
homeostasis model assessment (HOMA) and a quantitative insulin sensitivity check index (QUICKI), 148 
respectively. Leptin was quantified by a double-antibody RIA method (Linco Research, Inc., St. Charles, MO, 149 
USA)  (14, 15). Intra- and inter-assay coefficients of variation were 6.7 and 7.8%, respectively. All reported 150 
investigations were carried out in accordance with the principles of the Declaration of Helsinki, as revised in 151 
2013, and approved by the Hospital’s Ethical Committee for Research (061/2014). Written informed consent 152 
was obtained from all participants. 153 
2.2. Adeno-associated vectors 154 
AAV vectors, serotype 9, were used to drive the expression of GFP (AAV9-GFP) or hCPT1AM (AAV9-155 
hCPT1AM) in mouse liver. Plasmid vectors carried: a) the human albumin enhancer element and the human 156 
1-antitrypsin (EalbAATp) liver-specific promoter described by Kramer et al.  (16), b) the cDNA sequence of 157 
GFP or hCPT1AM, c) The woodchuck posttranscriptional regulatory element (WPRE, acc #AY468-486) (17), 158 
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d) The bovine growth hormone polyadenosine transcription termination signal [bGH-poly(A)] (bases 2326-159 
2533 GenBank acc #M57764). The expression cassette was flanked by two-inverted terminal repeats (ITRs) 160 
derived from AAV2. The vector preparations used titres of 1.34x10
13
 and 1.16x10
13
 genome copies (gc)/ml for 161 
AAV9-GFP and AAV9-hCPT1AM, respectively.  162 
2.3. Animals 163 
The animal study was designed as follows: 40 seven-week-old male C57BL/6J mice were purchased from 164 
Janvier (SC-C57J-M) and housed in our animal facility for 1 week to acclimatize. Mice were kept at standard 165 
laboratory conditions (12 h light/dark cycle, 20–22 ºC). Animals were randomly assigned to one of the 166 
following groups: NCD-GFP, HFD-GFP, NCD-hCPT1AM and HFD-hCPT1AM. Five animals from each 167 
group were housed in the same cage. Next, mice were fed with either NCD (manufactured by TestDiet 168 
[catalogue number #58Y2], 10% kcal fat) of HFD (manufactured by TestDiet [catalogue number #58Y1], 60% 169 
kcal fat) for the entire duration of the experiment. This diet causes steatosis but not severe liver injury 170 
(fibrosis). Body weight was measured every week and blood glucose once a month. After 9 weeks of diet, most 171 
of the mice already showed an obese phenotype characterized by a significant increase in circulating levels of 172 
glucose and insulin and higher body weight than the control NCD-fed group. AAV9-hCPT1AM and AAV9-173 
GFP vectors were administered by tail vein injection with a single dose (1.5x10
12
 gc/kg). To do that, mice were 174 
anesthetized in the morning (~10 am) using isoflurane, and then placed in a restrainer for the tail-vein injection. 175 
After injection, mice were returned to their home cage and room. Eleven weeks after virus injection, mice were 176 
anesthetized using isoflurane and then killed by cervical dislocation in fasting conditions (6 h). The total 177 
duration of the HFD feeding paradigm was 20 weeks (9 weeks before AAV9 vector administration and 11 178 
weeks after that). The Animal Experimentation Ethics Committee of the University of Barcelona (CEEA-UB) 179 
approved all the procedures with mice. Permits 9611 and 9609 were obtained from the Government of 180 
Catalonia, according to European Directive 2010/63/EU.  181 
2.4. Construction of site-directed hCPT1AM 182 
hCPT1A wild-type (wt) cDNA (GenBank Access No. HGNC: 2328) was obtained by hCPT1A cDNA 183 
amplification from the HepG2 cell line. The primers used were: hCPT1AHindIII.for 184 
(5´´TCGATAAGCTTATAAAATGGCAGCTCACCAAGC3´) and hCPT1AEcoR1.rev 185 
(5´CATCCGGAATTCCTTTTTGGAATTAGAACTG3´). The amplification was cloned in pYES plasmid to 186 
obtain the construct pYEShCPT1Awt. Plasmid pYEShCPTIAM593S was constructed using the Quick-Change 187 
PCR-based mutagenesis procedure (Stratagene) with the YEShCPT1Awt plasmid as template. Appropriate 188 
substitutions and the absence of unwanted mutations were confirmed by sequencing the inserts in both 189 
directions using Applied Biosystems 373 automated DNA sequences. To check hCPT1AM insensitivity to 190 
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malonyl-CoA, we expressed the constructs containing hCPT1A wt and mutant (hCPT1AM) in yeast cells and 191 
then prepared cell extracts as described in (9) for the assay of CPT1 activity. S. cerevisiae was chosen as an 192 
expression system for hCPT1A wt and hCPT1AM because it does not have endogenous CPT1 activity. The 193 
cDNA of the hCPT1AM gene used in our study contains the NH2-terminal sequence that direct the protein to 194 
the mitochondria and two more sequences that codify for two α-helix fragments that insert this protein into the 195 
mitochondrial outer membrane  (18–20). 196 
2.5. Isolation of primary mouse hepatocytes  197 
The collagenase method was used to isolate primary mouse hepatocytes  (21). Livers were perfused with 198 
Hank’s balanced salt solution (HBSS, pH 7.4, 37ºC, gassed with 95% O2 and 5% CO2: 5.4 mM KCl, 0.44 mM 199 
KH2PO4, 138 mM NaCl, 4.17 mM NaHCO3, 0.338 mM Na2HPO4, 5.56 mM glucose, 50 mM HEPES, and 0.5 200 
mM EGTA) through the portal vein for 5 min at a rate of 5 ml/min. Then, livers were perfused with HBSS 201 
(without EGTA) containing 5 mM CaCl2 and 0.25% (w/v) collagenase IV (Sigma) for 15 minutes 202 
approximately. The liver was then removed and gently teased apart in HBSS, and the cell suspension was 203 
washed three times in HBSS. Cell viability as assessed by the trypan blue exclusion test was always higher than 204 
80%. Hepatocytes were seeded at a density of 3.5x10
6
 cells in 0.1% (w/v) gelatin-treated 25-cm
2
 flasks in 205 
DMEM medium (Gibco #11966), supplemented with 10% FBS, 10 mM glucose, 10 μg/ml streptomycin, 100 206 
units/ml penicillin, 100 nM dexamethasone (Sigma), and 100 nM insulin (Sigma).  207 
2.6. Fatty-acid oxidation 208 
Fatty-acid oxidation (FAO) to CO2 and acid-soluble products (ASPs), essentially consisting of acyl-carnitine, 209 
Krebs-cycle intermediates, and acetyl-CoA, was measured in isolated primary mouse hepatocytes cultured in 210 
25-cm
2
 flasks. Following cell attachment after isolation (approximately 5 h), the medium was replaced for 16 h 211 
by fresh FAO medium (DMEM medium containing 0.1% FA-free BSA, 1 mM carnitine, 20 mM glucose, 10 212 
nM insulin, 10 μg/ml streptomycin and 100 units/ml penicillin). Then the medium was replaced by fresh FAO 213 
medium containing 0.3 mM oleate and 1 μCi/ml [1-14C]oleic acid bound to 1% (w/v) BSA and hepatocytes 214 
were incubated for 3 h at 37°C in a CO2-free incubator. Oxidation to CO2 and ASPs was measured as described 215 
previously  (22).   216 
2.7. Isolation of mitochondria from liver and assay of CPT1 activity 217 
Mitochondrial-enriched fractions from cultured hepatocytes were obtained by differential centrifugation. 218 
Briefly, hepatocytes were scraped and resuspended in 2 ml of solution A (70 mM sucrose, 220 mM mannitol, 2 219 
mM EDTA, 5 mM HEPES and protease inhibitor cocktail from Roche, pH 7.4). Then cells were homogenized 220 
using a glass Wheaton-Dounce homogenizer (20 strokes with both the loose and the tight pestle) and 221 
centrifuged at 2,000 x g for 3 min at 4ºC. Next, the supernatant was centrifuged at 16,000 x g for 30 min at 4ºC. 222 
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Finally, the mitochondria-enriched pellet was resuspended in 50-100 µl of solution A. CPT1 activity was 223 
measured in 10 g of protein from those mitochondria-enriched fractions, using the radiometric method as 224 
described previously  (23). Concisely, the substrates L-[methyl-
3
H]carnitine and palmitoyl-CoA were added to 225 
the protein suspension and enzyme activity was assayed for 4 min at 30°C in a total volume of 200 l. Next, 226 
butanol was used to isolate the fraction containing the [
3
H]palmitoyl-carnitine and radioactivity was measured 227 
by liquid scintillation counting.  228 
2.8. Serum biochemical analyses  229 
Blood samples were obtained from the tails of awake mice after an overnight fast. Blood glucose concentrations 230 
were measured using a Glucometer Elite (Bayer). Serum insulin was measured by ELISA (Millipore). Plasma 231 
triacylglycerides, β-hydroxybutyrate, cholesterol, HDL cholesterol, AST, and ALT were determined 232 
enzymatically using commercial kits adapted to a COBAS 6000 autoanalyzer (Roche Diagnostics, Rotkreuz, 233 
Switzerland)  (24).  234 
2.9. Glucose tolerance test  235 
For the GTT, glucose (2.0 g per kg body weight) was dissolved in PBS and administered by intraperitoneal 236 
injection after an overnight fast. Then, blood glucose concentrations were measured using a Glucometer Elite 237 
(Bayer) before, 15, 30, 60, 90, and 120 min after administration.  238 
2.10. Analysis of insulin/AKT signaling pathway in hepatocytes  239 
Analyses of insulin/AKT signaling were performed in isolated primary mouse hepatocytes. Sixteen hours after 240 
isolation, cells were incubated with 100 nM insulin (Humulin 100 UI/mL, Lilly) for 5 minutes. After that, 241 
protein extracts from cells were used to measure phosphorylation of AKT using Western blot, as described 242 
below.   243 
2.11. Western blot  244 
Protein determination by Western blot was performed using standard methods. CPT1A detection was 245 
undertaken in mitochondria-enriched fractions. The antibodies used are the following: Rabbit CPT1A-specific 246 
polyclonal antibody produced in our laboratory against amino acids 317-430 of the rat CPTIA  (10), Sci Crunch 247 
Cat# CPT1A, RRID:AB_2636894 (1:6000 in 5% Milk PBS-Tween); LC3B, Cell signaling #2775 (1:1000 in 248 
5% Milk PBS-Tween); SQSTM/p62, Cell signaling #5114S (1:1000 in 5% Milk PBS-Tween); PLIN2, Abcam 249 
#Ab37516 (1:200 in 5% Milk PBS-Tween); PLIN5, Abcam #Ab192749 (1:2000 in 5% Milk PBS-Tween); 250 
LDLr, Abcam #Ab52818 (1:1500 in 5% Milk PBS-Tween); LRP1, Abcam #Ab92544 (1:7000 in 5% Milk 251 
PBS-Tween); VLDLr, Santa Cruz #sc-18824 (1:1500 in 5% Milk PBS-Tween); TIM44, BD Bioscience 252 
#612582 (1:5000 in 5% Milk PBS-Tween); pAkt (Ser473), Cell signaling #4051S (1:1000 in 5% Milk PBS-253 
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Tween); Akt, Cell signaling #9272S (1:1000 in 5% Milk PBS-Tween); UCP2, Cell signaling #89326 (1:1000 in 254 
5% Milk PBS-Tween); HMGS2, produced in our laboratory (1:6000 in 5% Milk PBS- -actin, Sigma 255 
Aldrich #A3854 (1:50.000 in PBS-Tween); Total OXPHOS Rodent WB Antibody Cocktail, Abcam #ab110413 256 
(1:5000 in 5% Milk PBS-Tween); Lipolysis Activation Antibody Sampler Kit, Cell signaling #8334 (for all 257 
antibodies 1:1000 in 5% Milk PBS-Tween); ATGL, Cell signaling #2138 (1:1000 in 5% Milk PBS-Tween).   258 
2.12. Measurements of liver TAG content  259 
To measure TAG content in the liver, 100 mg of frozen tissue were homogenized in 500 μl PBS. Then, 260 
chloroform-extracted lipids were dried under an N2 stream and dissolved in isopropanol. TAG were quantified 261 
in the extracted lipids using the Cromatest Triglycerides MR kit (Linear Chemicals S.L.).  262 
2.13. ATP extraction and measurement 263 
Frozen liver samples were powdered and homogenized in 1.0 mL of 40% ice-cold HCLO4 and incubated for 10 264 
minutes. The precipitated proteins were removed by centrifugation (10,000 x g for 10 minutes). Next, 300 μl of 265 
the supernatant was neutralized by 5 M KHCO3. Then, 10 L was pipetted into the wells of a white 266 
267 
of ATP monitoring reagent (Molecular Probe, Life Technologies A22066). ATP concentrations were calculated 268 
from a calibration curve constructed at the same time by means of standard ATP dissolved in the appropriate 269 
solution for each experiment. 270 
2.14. Measurement of oxygen consumption in isolated mitochondria  271 
Respiration of isolated liver mitochondria (500 µg protein) was measured at 37ºC by high-resolution 272 
respirometry with the Oxygraph-2k (OROBOROS INSTRUMENTS, Innsbruck, Austria). Mitochondria were 273 
obtained in buffer II (sucrose 0.5 M, KCl 50 mM, EDTA 5 mM, sodium pyrophosphate 1 mM, MgCl2 5 mM, 274 
pH 7.4, and protease inhibitors) and 500 µl of mitochondria was brought to a final volume of 2.1 ml with 275 
respiration medium (EGTA 0.5 mM, MgCl2.6H2O 3 mM, taurine 20 mM, KH2P04 10 mM, HEPES 20 mM, 276 
BSA 1 g/l, K-lactobionate 60 mM, sucrose 110 mM, pH 7.1) and added into the oxygraph chamber. All 277 
respiration measurements were made in triplicate. Resting respiration (state 4, absence of adenylates) was 278 
assessed by the addition of 10 mM glutamate and 2 mM malate as the complex I substrate supply. Then, state 3 279 
respiration was assessed by the addition of 2.5 mM ADP. RCR was calculated as the quotient state 3/state 4. 280 
The integrity of the outer mitochondrial membrane was established by the addition of 10 μM cytochrome c and 281 
no stimulation of respiration was observed. The addition of 10 mM succinate provided state 3 respiration with 282 
parallel electron input to complexes I and II. The concentrations of substrates and inhibitors used were based on 283 
prior experiments conducted for optimization of the titration protocols. 284 
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2.15. Measurements of liver temperature  285 
The thermal images from mice liver were made using a FLIR T420 infrared camera (FLIR T420 Systems AB, 286 
Sweden) with thermal sensitivity of 0.05ºC and resolution set at 320 x 240 pixels. Mice were anesthetized and 287 
their abdominal cavity was opened. The first image was taken of a piece of aluminum foil to obtain a 288 
measurement of the reflected temperature for each set of images. To take the images, the camera was placed 30 289 
cm from the midpoint of the liver. Thermal data were extracted from the pictures using a region of interest 290 
(ROI)-based approach. The ROIs were manually drawn in the images of the liver region using FLIR Research 291 
IR Max software version 4.40.6.24 for Windows (FLIR Systems Inc., North Billerica, MA, USA). The reflected 292 
temperature was obtained by placing a rounded ROI on the aluminum foil image and retaining the mean value 293 
(ºC) for adjustments. Images were not normalized by liver size or weight, since the thermographic camera 294 
measures the minimum and maximal temperatures for a given ROI. Thus, these measurements do not vary 295 
according to liver size or weight  (25).  296 
2.16. RNA extraction and quantitative RT-PCR  297 
RNA extraction and quantitative RT-PCR were performed using standard procedures. Briefly, total RNA was 298 
extracted from frozen, pulverized tissue using the RNeasy kit (QIAGEN). Then, cDNA was synthesized with 299 
the Transcriptor First Strand cDNA Synthesis kit (Roche). For PCR amplifications, the LightCycler 480 SYBR 300 
Green I Master kit (Roche) was used and measured with the Roche LightCycler 480 Real-Time PCR System. 301 
The sequences of the oligonucleotides used are:  302 
Abca1 For: 5’-TTCTTGCGATACACTCTGGTGC Rev: 5’-CGGGATTGAATGTTCTTGTCGT;  303 
Atgl For: 5’-TGACCATCTGCCTTCCAGA Rev: 5’-TGTGGTGGCGCAAGAACA;  304 
Atg7 For: 5’-CCGGTGGCTTCCTACTGTTA Rev: 5’-AAGGCAGCGTTGATGACC;  305 
β-actin For: 5’-ATGCTCCCCGGGCTGTAT Rev: 5’-CATGGAGTCCTTCTGACCCAT;  306 
Hsl For: 5’-GCGCTGGAGGAGTGTTTTT Rev: 5’-CGCTCTCCAGTTGAACCAAG;  307 
Mgl For: 5’-TGAGAAAGGCTTTAAGAACTGGG Rev: 5’-GACCACCTGTGTGATGTGGG;  308 
Mtp For: 5’-GTGGAGGAATCCTGATGGTGA Rev: 5’-TGATCTTGGTGTACTTTTGCCC;  309 
hcpt1a For: 5’-CAATCGGACTCTGGAAACG Rev: 5’-CCGCTGACCACGTTCTTC. 310 
For Abcg8c and Abcg5 gene expression analyses, cDNA was subjected to real-time PCR amplification using 311 
Taqman Master Mix (Applied Biosystems) and specific mouse Taqman probes (Applied Biosystems) 312 
(Mm00446241_m1 [Abcg5] and Mm00445970_m1 [Abcg8]). 313 
2.17. Oil Red O staining in hepatocytes 314 
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TAG content in isolated primary mouse hepatocytes was measured using Oil Red O staining (Sigma, O0625), 315 
following standard procedures. Oil Red O stock solution was prepared in isopropanol (3 mg/ml). It was then 316 
filtered after overnight agitation and stored protected from light. The Oil Red O working solution was prepared 317 
by diluting the stock 3:2 in distilled water. Sixteen hours after hepatocyte isolation, cells were washed twice 318 
with PBS and fixed using formalin 4% formaldehyde for 30 minutes at room temperature. After fixation, 319 
hepatocytes were washed again with PBS and then permeabilized for 30 minutes with 60% isopropanol. Next, 320 
cells were incubated with Oil Red O working solution for 15 minutes. Finally, cells were washed with water 321 
and examined under the microscope. Lipid-packed vesicles appear as bright red after Oil Red O staining.  322 
2.18. Autophagy Flux Assay 323 
Autophagy/LC3II flux was performed in isolated primary mouse hepatocytes. Sixteen hours after isolation cells 324 
or 6 hours. After that, protein extracts from cells were used to 325 
measure LC3II protein levels using western blot, as described below. Autophagy flux was calculated by 326 
subtracting the densitometry values of LC3II in CQ untreated from CQ treated samples. 327 
2.19. Determination of acylcarnitine content 328 
To determine acylcarnitines in liver and serum samples, 140 l of serum and tissue homogenate was used for 329 
acylcarnitine extraction. First, 10 l of Deuterated palmitoylcarnitine [20 M] was added to get 200 pmol in 330 
150 uL of final resuspension. Next, 750 l of Folch reagent (chloroform:metanol 2:1), 100 l of dH2O and 50 331 
l 0.1M KOH were added to the samples. Phases were separated after vortexing and centrifugation at 2000 rcf. 332 
Following, the top aquous phase was carefully removed and the organic phase containing the acylcarnitines was 333 
washed with 200 l methanol:dH2O:chloroform (48:47:3). After washing, the organic solvent was dried using a 334 
SpeedVac vacuum concentrator. The day of the analyses, samples were resuspended with 150 l of methanol. 335 
Acylcarnitines were analysed using an Acquity UPLC-TOF system (Waters) with an BEH C8 column (1.7 mm 336 
particle size, 100 mm62.1 mm, Waters). The two mobile phases were 1 mM ammonium formate in methanol 337 
(phase A) and 2 mM ammonium formate in H2O (phase B), both phases with 0.05 mM formic acid. The 338 
following gradient was programmed: 0 min, 65% A; 10 min, 90% A; 15 min, 99% A; 17 min, 99% A; 20 min, 339 
65% A, and a flow rate of 0.3 mL min-1. Quantification was carried out using the extracted ion chromatogram 340 
of each compound, using 50- mDa windows. The linear dynamic range was determined by injecting standard 341 
mixtures. Positive identification of compounds was based on the accurate mass measurement with an error , 5 342 
ppm and their LC retention time compared to that of a standard (62%). 343 
2.20. Lipidomic analyses 344 
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Phospholipids and neutral lipids. A total of 750 µl of a methanol-chloroform (1:2, vol/vol) solution containing 345 
internal standards (16:0 D31_18:1 phosphocholine, 16:0 D31_18:1 phosphoethanolamine, 16:0 D31-18:1 346 
phosphoserine, 17:0 lyso-phosphocholine, 17:1 lyso-phosphoethanolamine, 17:1 lyso-phosphoserine, 17:0 347 
D5_17:0 diacylglycerol,  17:0/17:0/17:0 triacylglycerol and C17:0 cholesteryl ester, 0.2 nmol each, from 348 
Avanti Polar Lipids) were added to 0.020 ml serum. Samples were vortexed and sonicated until they appeared 349 
dispersed. They were extracted at 48°C overnight. The samples were then evaporated and transferred to 1.5 ml 350 
Eppendorf tubes after the addition of 0.5 ml of methanol. Samples were evaporated again and resuspended in 351 
150 µl of methanol. The tubes were centrifuged at 13,000 g for 3 min, and 130 µl of the supernatants was 352 
transferred to ultra-performance liquid chromatography (UPLC) vials for injection and analysis. 353 
Sphingolipids. A total of 750 µl of a methanol-chloroform (2:1, vol/vol) solution containing internal standards 354 
(N-dodecanoylsphingosine, N-dodecanoylglucosylsphingosine, N-dodecanoylsphingosylphosphorylcholine, 355 
and C17-sphinganine, 0.2 nmol each, from Avanti Polar Lipids) were added to 0.05 ml serum. Samples were 356 
extracted at 48°C overnight and cooled. Then, 75 µl of 1 M KOH in methanol was added, and the mixture was 357 
incubated for 2 h at 37°C. Following addition of 75 µl of 1 M acetic acid, samples were evaporated to dryness, 358 
and stored at -20°C until analysis. Before analysis, 150 µl of methanol were add to the samples, centrifuged at 359 
13,000 g for 5 min and 130 µl of the supernatant were transferred to a new vial and injected. 360 
LC-HRMS analysis was performed using an Acquity ultra high-performance liquid chromatography (UHPLC) 361 
system (Waters, USA) connected to a Time of Flight (LCT Premier XE) Detector. Full scan spectra from 50 to 362 
1800 Da were acquired, and individual spectra were summed to produce data points each of 0.2 sec. Mass 363 
accuracy at a resolving power of 10,000 and reproducibility were maintained using an independent reference 364 
spray via the LockSpray interference. Lipid extracts were injected onto an Acquity UHPLC BEH C8 column 365 
(1.7 µm particle size, 100 mm x 2.1 mm, Waters, Ireland) at a flow rate of 0.3 mL/min and a column 366 
temperature of 30ºC. The mobile phases were methanol with 2 mM ammonium formate and 0.2% formic acid 367 
(A)/water with 2 mM ammonium formate and 0.2% formic acid (B). A linear gradient was programmed as 368 
follows: 0.0 min: 20% B; 3 min: 10% B; 6 min: 10% B; 15 min: 1% B; 18 min: 1% B; 20 min: 20% B; 22 min: 369 
20% B.  370 
Sphingolipids (Cer, ceramide; SM, sphingomyelin; GlucCer, glucosylceramide; HexCer: hexosylceramides), 371 
glycerophospholipids (PC, phosphatidylcholine; LPC: lysophosphatidylcholine; pPC: plasmanylcholine; LPEA: 372 
lysophosphatidylethanolamine; and PC O-: ether-linked phosphatidylcholine), neutral lipids (DAG: 373 
diacylglycerol; TAG: triacylglycerol; CE: cholesterol ester). All Lipid species are annotated using the “lipid 374 
subclass” and “C followed by the total fatty acyl chain length:total number of unsaturated bonds” and (e.g., PC 375 
(C32:2)).  376 
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2.21. Statistical analysis  377 
Data are presented as mean ± S.E.M. For the statistical analyses, we used analyses of variance considering two 378 
factors (two-way ANOVA: factor one was diet [NCD or HFD] and factor two was the virus injected [AAV-379 
GFP or AAV-hCPT1AM]), followed by Tukey’s multiple comparison test. For the lipidomic studies of mice 380 
samples, we used two-way ANOVA analysis, correcting for multiple comparisons by controlling the false 381 
discovery rate (FDR) (two-stage step-up method of Benjamini, Kieger and Yekutieli). Hierarchical clustering 382 
was performed using R  (26). For these analyses, pre-processed lipidomics data was log-transformed and 383 
normalized between samples using limma package  (27). To avoid mathematical errors, before log-384 
transformation zeros were substituted by 1/10th of the minimum value (other than zero) in the data matrices. 385 
Hierarchical unsupervised clustering was performed using heatmap3 package  (28), applying complete linkage 386 
on the euclidean distances matrices. For the analysis of human lipidomic measurements, principal component 387 
analyses (PCA) were performed using the function prcomp from R base after scaling the log-transformed data 388 
to account for the large numerical differences among the mean values of the different lipidic molecules. UMAP 389 
analyses were performed on log-transformed data using R umap package  (29) that implements the Uniform 390 
Manifold Approximation and Projection method  (30). The lipid content change (ΔLC) was calculated for every 391 
lipid in obese patients as the difference in the log-transformed content of that particular lipid after surgery vs 392 
before surgery. Similarly, changes in NAFLD-related parameters were calculated in obese patients as the 393 
difference in those parameters after surgery. Partial correlations between ΔLC and changes in NAFLD-related, 394 
correcting for age, gender and changes in BMI were calculated using the package ppcor (31) and visualized 395 
using corrplot package (32). Essentially, the partial correlation analyses evaluated the lineal regression equation 396 
‘ΔNAFLD.variable ~ age + gender + ΔBMI + Δlipid.content’, where ΔNAFLD.variable was the change in the 397 
studied variable (i.e. glucose, AST, ALT, GGT or ADT/ALT) after surgery, ΔBMI was the change in BMI after 398 
surgery and Δlipid.content was the change of the studied lipid after surgery. When required, p-values were 399 
adjusted for multiple testing using the false discovery method (FDR)  (33) implemented in the function 400 
p.adjust. When very strong correlation among tests was expected (for instance, in the partial correlation 401 
analyses), no further p-value adjustment was applied to minimize type-II errors. Differences were considered 402 
significant at P < 0.05.  403 
3. Results 404 
3.1. AAV9-mediated expression of hCPT1AM in mouse liver increases FAO 405 
We used AAVs to express a human mutated isoform of CPT1A (hCPT1AM) or green fluorescent protein 406 
(GFP), which was used as a control (AAV9-hCPT1AM and AAV9-GFP, respectively). The genome of each 407 
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virus contained the target gene under the control of the liver-specific promoter EalbAATp, which constrained 408 
the expression of hCPT1AM to this tissue (Fig. S1A).  409 
Eight-week old C57Bl/6J mice were fed either NCD or HFD for 9 weeks. After that time, mice showed an 410 
obese phenotype characterized by a significant increase in circulating levels of glucose and insulin and higher 411 
body weight than the control NCD-fed group (Fig. S1B-C). NCD- and HFD-fed mice were then administered 412 
1.5x10
12
 gc/kg of AAV9-GFP or AAV9-hCPT1AM by tail-vein injection (Fig. 1A). Mice were studied 413 
throughout the treatment and killed at 11 weeks after AAV administration. At that time point, most hepatocytes 414 
expressed GFP in both NCD- or HFD-fed mice treated with AAV9-GFP, which indicated that the infection 415 
efficiency was similar in both groups (Fig. S2A). As expected, mRNA expression of hCPT1A was observed in 416 
NCD-hCPT1AM and HFD-hCPT1AM mice but not in their respective GFP controls (Fig. S2B). In addition, 417 
CPT1A protein levels were 2- and 1.7-fold higher in NCD-hCPT1AM and HFD-hCPT1AM mice, respectively, 418 
than in their GFP controls (Fig. S2C). Note that the CPT1A antibody recognizes both endogenous CPT1A and 419 
the expressed hCPT1AM protein. Concomitantly, CPT1 activity was 1.62-fold higher in NCD-hCPT1AM  420 
mice and 1.42-fold higher in HFD-hCPT1AM mice than in their respective GFP controls (Fig. 1B). To discard 421 
changes in mitochondrial content due to hCPT1AM expression, we analyzed mitochondrial protein TIM44 422 
(translocase of the mitochondrial inner membrane) levels in the liver of all mice. No differences were seen in 423 
mitochondrial content between groups (Fig. S2D). CPT1A protein levels in other tissues with strong AAV9 424 
tropism, such as heart and skeletal muscle (hamstring), did not change after administration of AAV9-425 
hCPT1AM (Fig. S2E).  426 
Consistent with increased CPT1 protein and activity, the levels of long-chain acylcarnitines, which are direct 427 
products of CPT1A activity, were increased in the liver of hCPT1AM-expressing mice compared to GFP-428 
expressing controls (Fig. 1C). Conversely, long-chain acylcarnitine concentrations in serum samples were 429 
similar amongst all groups (Fig. 1C). Moreover, FAO was 32% higher in cultured primary hepatocytes from 430 
HFD-hCPT1AM mice than in HFD-GFP controls (Fig. 1D). The same was true in hepatocytes from NCD-431 
hCPT1AM mice, albeit to a lesser extent. 432 
3.2. hCPT1AM expression in mouse liver reduces hepatic steatosis, hepatic insulin resistance, hyperglycemia 433 
and hyperinsulinemia 434 
HFD-hCPT1AM mice weighed significantly less than HFD-GFP control mice, whereas no differences were 435 
seen in NCD-hCPT1AM mice (Fig. 1E and Table 1). The differences in body weight were not attributable to 436 
changes in food consumption, since daily rates of food intake were equal in GFP- and hCPT1AM-expressing 437 
mice fed either NCD or HFD (Fig. S3A). Fasting blood glucose and insulin levels were lower in HFD-438 
hCPT1AM mice than in control HFD-GFP mice, and similar to levels observed in NCD-treated mice (Fig. 1F-439 
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G). Glucose tolerance (measured via intraperitoneal GTT) was improved in HFD-hCPT1AM mice compared to 440 
HFD-GFP control mice (Fig. 1H). In addition, pAkt levels were higher in cultured primary hepatocytes from 441 
HFD-hCPT1AM mice than in those from HFD-GFP mice, as shown in Fig. 1I. Overall, these results indicate 442 
that hCPT1AM expression improves hepatic insulin signaling and the obesity-induced diabetic phenotype 443 
observed in HFD-fed mice.  444 
Liver weight and TAG content of HFD-hCPT1AM mice were lower than in HFD-GFP control mice (Fig. 2A, 445 
Table 1 and Fig. S3B). In addition, histopathological analysis of liver samples confirmed that HFD-hCPT1AM 446 
mice showed a reduction in the NAFLD activity score (NAS) (34) (Table S1). Furthermore, hepatocellular 447 
ballooning was not observed in any of the HFD-hCPT1AM mice (Table S1). Of note, hCPT1AM expression 448 
did not significantly affect liver histological parameters in NCD-fed mice (Fig. 2A and Table S1). Finally, 449 
hepatic injury was lower in HFD-hCPT1AM mice than in HFD-GFP controls, as indicated by lower serum 450 
levels of AST and ALT enzymes (Table 1). In summary, these results indicate that hepatic hCPT1AM 451 
expression decreases HFD-induced hepatic steatosis and injury. 452 
3.3. Increased liver FAO activates mitochondrial energy metabolism  453 
Increased FAO due to hCPT1AM expression could produce a surplus of acetyl-CoA that can be metabolized by 454 
two pathways: 1) conversion to ketone bodies and 2) entry to the tricarboxylic acid (TCA) cycle to complete 455 
oxidation. Oxidation of acetyl-CoA can be coupled to ATP synthesis or not, in which case uncoupling protein 2 456 
(UCP2) allows the dissipation of energy as heat. First, we analyzed liver protein levels of mitochondrial 457 
hydroxymethylglutaryl-CoA synthase 2 (HMGCS2), the rate-limiting enzyme of hepatic ketogenesis. 458 
HMGCS2 protein levels were higher in hCPT1AM-expressing mice than in GFP control mice in both NCD- 459 
and HFD-fed groups (Fig. 2B). In addition, serum levels of ketone bodies such as β-hydroxybutyric acid (BHB) 460 
were higher in HFD-hCPT1AM mice than in HFD-GFP control mice (Table 1). These results suggest that 461 
excess substrates in HFD-hCPT1AM mice promote the production of ketone bodies. Second, we observed that 462 
temperature and UCP2 protein levels were higher in the liver of HFD-hCPT1AM mice than in the HFD-GFP 463 
control group, which indicates an increase in energy dissipation (Fig. 2B-C). Finally, liver ATP levels were 464 
higher in HFD-hCPT1AM mice than in control HFD-GFP mice (Fig. 2D), whereas no differences were 465 
observed in NCD-fed mice. Altogether, these results indicate that hCPT1AM expression increments FAO in 466 
liver, resulting in an increase in ketogenesis and oxidative phosphorylation, both uncoupled and coupled to 467 
ATP synthesis.  468 
Moreover, HFD reduced the mitochondrial respiratory control ratio (RCR) in GFP-expressing mice but not in 469 
hCPT1AM-expressing mice. This indicates higher respiratory coupling efficiency in liver mitochondria from 470 
HFD-fed hCPT1AM-expressing mice (Fig. 2E and S3C). The protein levels of the OXPHOS complexes CV-471 
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ATP5A, CIV-MTCO1, CII-SDHB and CI-NDUFB8 were similar in HFD-hCPT1AM and HFD-GFP control 472 
mice (Fig. S3D). No alteration in the mRNA levels of the genes involved in mitochondrial dynamics was 473 
observed in any of the experimental groups (Fig. S4A). 474 
3.4. hCPT1AM expression activates autophagy in liver  475 
Because the expression of hCPT1AM in the liver of HFD-fed mice decreases the accumulation of lipid droplets 476 
(LD) (Table 1, Fig. 2A and S3B), we next examined the two main catabolic pathways of LDs: lipolysis and 477 
autophagy. First, we measured the levels of perilipin 2 and 5 (PLIN2 and PLIN5), which are key components of 478 
the LDs and considered regulators of lipolysis (35). HFD-induced increase in PLIN2 and PLIN5 protein levels 479 
was blunted in hCPT1AM-expressing mice (Fig. 3A). Next, we analyzed the mRNA levels of the genes Atgl, 480 
Hsl and Mgl, which encode enzymes involved in the lipolysis pathway. In all cases, values were higher in HFD-481 
hCPT1AM than in HFD-GFP control mice (Fig. S4B). However, no changes were observed when we analyzed 482 
the protein concentrations of the lipases ATGL and the phosphorylated active form of HSL (Fig. S4C). 483 
Altogether, these results suggest that the decrease in LD observed in HFD-hCPT1AM mice is independent of 484 
the LD-associated lipases activity.  485 
Recent studies have revealed a role for autophagy in LD breakdown  (36, 37). Therefore, next we analyzed the 486 
expression of autophagy-related protein 7 (Atg7) and the protein levels of the LC3II/LC3I ratio and p62, 487 
autophagy biomarkers. ATG7 is a key protein in LC3II formation during the initial steps of the autophagy 488 
process. We observed that Atg7 mRNA levels were higher in HFD-hCPT1AM than in HFD-GFP control mice, 489 
which indicates an increase in the machinery to activate autophagy (Fig. 3B). Moreover, the LC3II/LC3I ratio 490 
was higher and p62 protein levels were lower in HFD-hCPT1AM mice than in the HFD-GFP group (Fig. 3C). 491 
Accumulation of LC3II in the presence of Chloroquine (CQ) indicates its flux through lysosomes. Of note, 492 
quantification of LC3II flux revealed an induction of autophagy in cultured hepatocytes from hCPT1AM-493 
expressing mice when compared to GFP controls (Fig. 3D). Altogether, these results suggest that hCPT1AM 494 
expression in HFD-fed mice increases the expression of the machinery of autophagosome formation. 495 
3.5. hCPT1AM expression improves cholesterol levels in HFD-fed mice 496 
HFD-hCPT1AM mice showed considerably lower total and LDL-cholesterol in serum than obese HFD-GFP 497 
control mice (Table 1). To determine which mechanisms might be involved in the observed low serum 498 
cholesterol levels we analyzed: 1) mRNA levels for the key enzyme HMG-CoA reductase and the transcription 499 
factor SREBP-2 (both involved in de novo cholesterol synthesis), 2) protein levels of liver lipoprotein receptors, 500 
and 3) mRNA levels for transporters involved in liver cholesterol export. Our results showed no changes in 501 
HMG-CoA reductase and SREBP-2 mRNA levels due to hCPT1AM expression (Fig. S4D). We next measured 502 
protein levels of liver lipoprotein receptors involved in the import and export of liver cholesterol. Specifically, 503 
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we analyzed LDLr (low-density lipoprotein receptor), VLDLr (very low-density lipoprotein receptor), and 504 
LRP1 (low-density lipoprotein receptor-related protein). HFD-induced increase in LDLr protein levels was 505 
blunted in hCPT1AM-expressing mice (Fig. 3E). No significant changes were observed in VLDLr and LRP1 506 
protein levels. The mRNA levels for MTP (microsomal transporter protein), a protein involved in ApoB 507 
formation, were lower in HFD-GFP than in NCD-GFP mice and did not change after the expression of 508 
hCPT1AM (Fig. 3F). The mRNA levels for ABCA1 and ABCG5/G8 transporters, which are involved in 509 
cholesterol export, were lower in obese HFD-GFP mice. However, hCPT1AM expression was sufficient to 510 
revert the decrease caused by HFD (Fig. 3F). Altogether, these results suggest that some aspects of liver 511 
cholesterol metabolism are improved in HFD-hCPT1AM mice, which could explain the reduction in total 512 
serum cholesterol levels observed in these mice. 513 
3.6. Comparative liver and serum lipidomic analysis of AAV9-hCPT1AM-treated mice shows a specific 514 
lipidomic signature to monitor hepatic steatosis  515 
Reliable non-invasive methods to monitor NAFLD remain limited. Here, we aimed to uncover serum lipid 516 
biomarkers for non-invasive clinical detection and monitoring of hepatic steatosis. We performed a 517 
comparative lipidomic study in liver and serum samples from NCD- and HFD-fed mice expressing either GFP 518 
or hCPT1AM. We analyzed 66 species of sphingolipids, 16 species of glycerophospholipids, and 94 species of 519 
neutral lipids by electrospray ionization mass spectrometry (ESI-MS). In the liver, a subset of 42 lipids 520 
exhibited statistically significant differences among NCD-GFP and HFD-GFP groups (2-way ANOVA P<0.01 521 
adjusted for multiple comparisons using FDR) (Fig. 4A). Noteworthy, expression of hCPT1AM in HFD-fed 522 
mice restored the levels of 30 of these lipid species to what is seen in NCD-fed mice (shown in red in Fig. 4A). 523 
These include ceramides (Cer (C16:0, C18:0, C20:0, and C22:0)), dihydroceramides (dhCre (C22:0)) and 524 
phospholipids, specifically lysophosphatidylcholines (LPC (C16:0 and C18:0)). However, the most significant 525 
changes were observed in the levels of neutral lipids, such as DAG and TAG. While the livers of HFD-GFP 526 
mice show a vast increase in the levels of DAG and TAG, specifically those with a long chain fatty acyl group, 527 
the expression of hCPT1AM in HFD-fed mice was sufficient to reverse the accumulation of these lipid species 528 
(Fig. 4A). The clustering analysis was performed using complete linkage method on the euclidean distances of 529 
the log-transformed values of the 42 liver lipid biomarkers that showed statistically significant differences 530 
based on the type of diet. Accordingly, the classification provided by the clustering analysis mainly reflected 531 
the difference in diet, albeit it also clearly showed differences between the HFD-fed animals expressing 532 
hCPT1AM (all of them in the cluster in red) vs those expressing the control GFP protein (all but one in the 533 
cluster in green) (Fig. 4A).  As expected, not all the lipid species that changed in the liver of HFD-hCPT1AM 534 
mice were also changed in serum. As shown in Fig. 4B, a subset of 24 lipids exhibited statistically significant 535 
differences between HFD-fed and NCD-fed mice (two-way ANOVA, P < 0.01 adjusted for multiple 536 
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comparison using the FDR method). Expression of hCPT1AM in HFD-fed mice reverted the levels of 10 of 537 
these lipid species to what is seen in NCD-fed mice (shown in red in Fig. 4B). Among them, we found that 538 
ceramide Cer (C20:0) was lower in the serum of HFD-hCPT1AM mice than in that of HFD-GFP control mice 539 
(Fig. 4B). Several species of glycerophospholipids were also reduced in HFD-hCPT1AM serum, including 540 
phosphatidylcholines (PC (C34:1, C36:3, C36:4 and C38:6)), plasmalogen (pPC (C32:0)) and 541 
lysophosphatidylethanolamine (LPEA (C18:0)). Finally, only a few neutral lipids (DAG (C32:5) and TAG 542 
(C50:1)) showed significantly lower levels in the serum of HFD-hCPT1AM mice than in that of HFD-GFP 543 
control mice. As before, the clustering analysis was performed using complete linkage on the euclidean 544 
distances of the log-transformed values of the selected lipids. In this case, the analysis yielded three main 545 
clusters, and a fourth cluster containing a single animal (HFD-GFP 2), most likely an outlier. In general, the 546 
differences among groups were not as pronounced as those found when studying liver lipids, and the separation 547 
between HFD-hCPT1AM and HFD-GFP animals was not as definite (Fig. 4B). Altogether, this comparative 548 
lipidomic analysis revealed that some lipid species (Cer (C20:0) and TAG (C50:1)) increase in the liver and 549 
serum of HFD-fed mice, yet the expression of hCPT1AM in the liver is sufficient to partially or totally revert 550 
this increase both in the tissue and in serum (Fig. 4C-D). Therefore, we hypothesized that these lipid species 551 
might be potential circulating biomarkers to monitor the amelioration of NAFLD during a therapeutic 552 
intervention. 553 
3.7. Serum lipidomic switch after bariatric surgery in obese humans 554 
Lipidomic analyses in mice highlighted interesting potential biomarkers for monitoring human NAFLD. To 555 
determine the clinical relevance of our findings, we performed a comparative serum lipidomic analysis of 15 556 
lean control subjects and 15 obese patients, before and 6 months after Roux-en-Y gastric bypass (RYGB) 557 
(Table 2). Obese patients were diagnosed with NAFLD by liver biopsy (Table 3) and did not receive any 558 
antidiabetic treatment before surgery. The only patient on statin medication did not require lipid-lowering 559 
therapy 6 months after surgery. After RYGB, obese patients showed lower weight and BMI (from 43.0± 1.2 to 560 
29.1 ±1 kg/m
2
), decreased leptin levels and overall improved clinical biochemistry (Table 2). We analyzed 46 561 
species of sphingolipids, 40 species of glycerophospholipids, and 50 species of neutral lipids (MAG, DAG, 562 
TAG and cholesterol esters) by ESI-MS in serum from lean control subjects and obese patients before and after 563 
RYGB.  564 
A subset of 26 lipids exhibited statistically significant differences among groups (ANOVA, P < 0.01 adjusted 565 
for multiple comparison using the FDR method) (Fig. 5A). Unsupervised clustering analyses yielded three 566 
clusters with a very strong association with the sample type (P = 2.2x10-10, Chi-squared test). Notably Cluster 567 
3, comprising most post-surgery individuals, was closer to Cluster 1 (mostly composed of lean control subjects) 568 
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than to Cluster 2 (mostly obese pre-surgery individuals). These 3 clusters were not associated with gender (P = 569 
0.55, Chi-squared test) or age (P=0.71, ANOVA).   570 
We also performed two complementary dimension reduction analyses, a classical principal component analysis 571 
(PCA) and a more sophisticated Uniform Manifold Approximation and Projection (UMAP), which is a non-572 
linear dimension reduction tool. In line with the results shown in Fig. 4A, the dimension reduction analyses 573 
showed that the serum lipidomics values of the obese post-surgery patients were closer to those of lean controls 574 
than to the patients before surgery (Fig. 5B). In the PCA, there was a very large difference in the first principal 575 
component mean value of obese pre-surgery patients with lean controls (difference = 10, P-adjusted = 4.7x10
-7
) 576 
and obese post-surgery patients (difference = 9.2, P-adjusted = 4.6x10
-6
), but not between lean and obese post-577 
surgery patients (difference = 0.8, P-adjusted = 0.87). Similarly, the first dimension of the UMAP (UMAP 1) 578 
revealed a significant difference between obese pre-surgery individuals and lean controls (difference = 2.1, P-579 
adjusted = 1.7x10
-6
), as well as with obese post-surgery individuals (difference = 3.1, P-adjusted = 1.5x10
-9
), 580 
but not between lean and obese post-surgery individuals (difference = 0.9, P-adjusted = 0.044).  581 
Next, we evaluated the correlation between changes in serum lipid profiles and NAFLD variables, adjusting for 582 
changes in BMI. First, we calculated the serum lipid content change (ΔLC = content after surgery - content 583 
before surgery) and its correlation with BMI change (ΔBMI) in obese patients subjected to RYGB surgery. 584 
Fifty-five of the lipids analyzed exhibited statistically significant changes after surgery (P < 0.05, paired t-test 585 
corrected for multiple comparisons), and only 8 showed a significant correlation with changes in BMI (P < 586 
0.05, correlation test corrected for multiple comparisons) (Fig. 5C). Notably, there was no overlap between the 587 
set of lipids with significant changes after surgery and those that best correlated with changes in BMI. In 588 
general, lipids with larger ΔLC showed weak correlation with ΔBMI and, conversely, lipids whose ΔLC 589 
strongly correlated with ΔBMI had very modest ΔLC. This observation suggests that the most significant 590 
changes in serum lipid content do not directly reflect the loss of BMI. 591 
When we compared the lipidomic analysis in mice serum and liver and human serum before and after 592 
therapeutic interventions such as AAV9-hCPT1AM administration and RYGB surgery respectively, we noticed 593 
that TAG (C50:1) was increased in obese/NAFLD mice and humans but recovered after hCPT1AM expression 594 
in mice and RYGB surgery in humans (Fig. 4D and Fig. 5D). As mentioned above, changes in TAG (C50:1) 595 
after bariatric surgery did not correlate with changes in BMI. Therefore, the putative correlation of TAG and 596 
NAFLD score is likely to be independent. Unfortunately, some parameters for calculating the NAFLD score 597 
were not available. Nonetheless, we evaluated the association between ΔLC and NAFLD-related parameters, 598 
such as glucose levels, the AST/ALT ratio, GGT levels, ALT levels and AST levels (Fig. 5E), correcting for 599 
age, gender and changes in BMI. As shown in Fig. 5E, changes in TAG (C50:1) after bariatric surgery show a 600 
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partial correlation with changes in NAFLD-related parameters. Altogether, these results highlight TAG (C50:1) 601 
as a potential circulating biomarker to monitor the amelioration of NAFLD during a therapeutic intervention.  602 
603 
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4. Discussion  604 
Here we describe a partial reversion of an already established obese and diabetic phenotype through an 605 
enhanced FAO therapeutic intervention. AAVs have become a focus of attention in the field, especially in 606 
clinical-stage experimental therapeutic strategies, and are considered one of the safest strategies for gene 607 
therapy (38). Two key factors of the present study are the use of the AAV9 serotype which efficiently and 608 
specifically targets hepatocytes and the use of the human isoform of CPT1AM (hCPT1AM) with the prospect 609 
of future clinical therapeutic applications. Thus, here we describe that AAV9-mediated hCPT1AM-expressing 610 
mice under HFD showed increased liver FAO and, importantly, reduced NAFLD and improved glucose 611 
tolerance and hepatic insulin signaling compared to HFD-fed control mice. In addition, hepatic hCPT1AM-612 
expression in HFD-fed mice is sufficient to reduce potentially toxic lipid intermediates in the liver, such as 613 
DAG and ceramides, that can activate protein kinase C (PKCƸ) resulting in an impairment in the insulin 614 
signaling pathway (39–42). These reduced ceramides and DAGs levels could explain the enhanced hepatic 615 
insulin signaling observed in HFD-hCPT1AM mice. Notably, hCPT1AM expression in NCD-fed mice did not 616 
significantly affect the hepatic and metabolic endpoints that were examined.  617 
The expression of hCPT1AM does not have any noticeable deleterious effect in the liver, yet it reverses hepatic 618 
injury as indicated by the lower serum levels of AST and ALT enzymes observed in HFD-hCPT1AM mice. 619 
However, it has been suggested that excessive FAO in muscle might lead to mitochondria overload and cell 620 
toxicity  (43). Here we show that in HFD-hCPT1AM mice, three mechanisms could prevent possible oxidative 621 
stress caused by the accumulation of FAO metabolites in the mitochondria. First, the surplus of acetyl-CoA 622 
generated from FAO activates the ketogenic pathway. Second, part of the acetyl-CoA enters the TCA cycle for 623 
complete oxidation and ATP synthesis. Third, part of the energy produced is dissipated as heat. Nonetheless, 624 
the parallel increase in mitochondrial uncoupled and coupled respiration observed after hCPT1AM expression 625 
might seem paradoxical. One possible explanation could lie in previous reports showing that mild uncoupling, 626 
caused by activation of UCP2, might attenuate mitochondrial ROS production and protect against ROS-related 627 
cellular damage  (44–48). We hypothesized that an increase in mitochondrial FAs import in HFD-hCPT1AM 628 
mice might trigger a mild uncoupling intended to mitigate ROS production. 629 
We examined the molecular mechanisms underlying the beneficial effects of hCPT1AM expression. Autophagy 630 
and lipolysis are two pathways implicated in the mobilization of lipid droplets (LDs) that are compromised 631 
after the onset of T2D and in genetic and diet-induced models of obesity  (36, 49–52). In HFD-hCPT1AM 632 
mice, increased FAO results in a remarkable reduction of hepatic LDs. Consistently, levels of the structural 633 
proteins PLIN2 and PLIN5 were also low in HFD-hCPT1AM mice. However, protein analyses indicated that 634 
expression of hCPT1AM does not result in the activation of LD-associated lipases. Instead, the autophagy 635 
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pathway appears to be activated in the liver of HFD-hCPT1AM mice. Importantly, recent studies have revealed 636 
a role for autophagy in hepatic LD breakdown  (37). Here, we propose that this mechanism could contribute to 637 
the reduction of hepatic lipid stores in HFD-hCPT1AM mice.   638 
HFD-hCPT1AM mice showed lower levels of serum LDL-cholesterol than HFD-GFP controls. Given that one 639 
of the main determinants of VLDL synthesis is hepatic TAG content, which is significantly reduced in HFD-640 
hCPT1AM mice, we speculate that secretion of VLDL might be reduced in HFD hCPT1AM-expressing mice. 641 
Consequently, the derived LDL levels are lower. Moreover, hCPT1AM expression in the liver restored some 642 
aspects of cholesterol metabolism, such as protein levels of lipoprotein transporters and mRNA levels of 643 
cholesterol transporters.  644 
There is great interest in finding new circulating biomarkers for NAFLD/NASH diagnosis and monitoring of 645 
treatment effectiveness. While some studies have analyzed specific lipid profiles in models of NAFLD, obesity 646 
and T2D (53–55), only a few studies have focused on changes of lipid species in liver and serum under 647 
interventions that improve hepatic steatosis and obesity. Here, we performed a comparative lipidomic analyses 648 
in mice and humans that aimed to look for potential non-invasive markers to monitor the progression of 649 
NAFLD in pathological conditions (i.e. obesity) before and after therapeutic interventions intended to reduce 650 
body weight and hepatic steatosis (i.e. AAV9-mediated hCPT1AM expression in mice and Roux-en-Y gastric 651 
bypass in humans). In mice, our results show that TAG with a longer, unsaturated chain of FAs (TAG 652 
(C50:1/2/3), TAG (C52:3/4/5) and TAG (C54:1/4/5/6)) increased in the liver of HFD-fed mice. However, the 653 
expression of hCPT1AM decreases the concentration of these lipid species back to what is seen in NCD-fed 654 
mice. Interestingly, one of these species, TAG (C50:1), follows the same pattern in the serum of HFD-655 
hCPT1AM, which suggests that this TAG could be a circulating biomarker of hepatic steatosis. These results 656 
are in line with a previous study showing that treatment of HFD-fed mice with compound K-enriched with 657 
ginsenosides, which decreases hepatic steatosis in treated mice, also reduced serum levels of TAG species with 658 
a total number of carbons above 50 (56).  659 
Remarkably, in the serum of patients with obesity and NAFLD, similar TAG species (TAG (C50:1/2/3) and 660 
TAG (C52:3/4)) are reduced 6 months after bariatric surgery. These results are in line with previous studies 661 
reporting a reduction in TAG (C50:1), amongst other TAGs, in plasma/serum of obese patients after RYGB 662 
interventions  (57, 58). Conceivably the mechanisms behind TAG changes might be different in humans and in 663 
hCPT1AM-expressing mice. In HFD-hCPT1AM mice the increase in hepatic FAO mobilizes stored lipid 664 
droplets and reduces the number of substrates for hepatic TAG synthesis. In humans, we can speculate that 665 
decreased intestinal fat absorption and altered hormone levels might reduce hepatic lipid accumulation. In our 666 
study, changes in many of these lipid content in the serum of obese patients after bariatric surgery correlate 667 
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with changes in NAFLD-related parameters and do not directly reflect the loss of BMI. Yet, the decrease in 668 
circulating TAG (C50:1) after RYGB could be mediated by other parameters beyond hepatic steatosis. 669 
Nonetheless, our results in mice and human samples support speculation on its possible role as a non-invasive 670 
biomarker for human NAFLD diagnosis and prognosis. Additionally, we cannot reject the possibility that other 671 
circulating lipid species that changed in our human intervention study, as well as in other published paper (58–672 
60) could be circulating biomarkers for NAFLD. It is important to note that our study did not investigate the 673 
role of CPT1A in human NAFLD or in the observed changes in serum lipidomic profiles after RYGB. 674 
Nonetheless, previous reports have shown that liver CPT1A expression is remarkably decreased in biopsy 675 
samples from NAFLD patients  (61, 62). This observation indicates that decreased β-oxidation in human 676 
NAFLD could contribute to fatty acid accumulation in hepatocytes. This suggests that our pre-clinical 677 
observations in mice could be relevant for future human research. Overall, the strength of our lipidomic study is 678 
based on the comparison of mice and human samples of hepatic steatosis, before and after therapeutic 679 
intervention. This strategy allows us to look for specific, robust serum biomarkers that reflect the progression of 680 
NAFLD and the effectiveness of a therapeutic intervention. In the future, the hypothesized candidate biomarker 681 
should be validated in a larger cohort of participants before it is used for clinical purposes. 682 
In summary, here we report an efficient gene therapy approach to greatly reduce liver steatosis and body weight 683 
and to improve glucose tolerance and hepatic insulin signaling in a mouse model of HFD-induced obesity (Fig. 684 
5F). Moreover, we shed light on the molecular mechanisms involved in the beneficial effects of increasing 685 
FAO in hepatocytes. Finally, based on a comparative lipidomic analysis of mouse and human samples, we 686 
hypothesize a candidate circulating biomarker to monitor obesity and hepatic steatosis and the effectiveness of 687 
therapeutic interventions (Fig. 5F). The future directions of this work should include long-term experiments (1 688 
year or more) in mice, rats and higher animal species (monkeys) to ratify the effectiveness of the gene therapy 689 
and identify potential long-term side effects or cytotoxicity. Moreover, studies in larger human cohorts would 690 
confirm the prospective clinical applicability of the suggested circulating biomarker. Altogether, our results 691 
point towards the human isoform of CPT1A as a potential therapeutic target against NAFLD and obesity-692 
induced disorders. 693 
694 
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Tables  721 
 NCD HFD 
 AAV-GFP AAV-hCPT1AM AAV-GFP AAV-hCPT1AM 
Body weight (g) 32.3 ± 0.86 32.7 ± 1.41 50.7 ± 0.99 # 45 ± 1.02 * 
Total CHOL (mg/dL) 105.0 ± 7.58 107.8 ± 9.06 205.2 ± 6.52 # 180.2 ± 7.36 * 
TAG (mg/dL) 39.8 ± 2.97   42.2 ± 7.14   42.8 ± 1.35 38.8 ± 1.74 
LDL CHOL (mg/dL) 29.8 ± 4.68 33.7 ± 4.32 117.2 ± 6.44 # 89.3 ± 6.28 * 
HDL CHOL (md/dL) 67.1 ± 2.91 65.6 ± 4.55 79.4 ± 0.96 82.6 ± 1.69 
BHB (mM)   1.2 ± 0.06   1.1 ± 0.08   1.5 ± 0.09 #   1.9 ± 0.10 * 
ALT (U/L) 8.3 ± 1.66 4.2 ± 1.72 109.2 ± 22.50 # 34 ± 5.75 * 
AST (U/L) 35.2 ± 5.31 27.3 ± 2.22 110.4 ± 18.33 # 67.2 ± 8.41 * 
Liver weight (g) 1.1 ± 0.04 1.1 ± 0.08 2.4 ± 0.12 # 1.5 ± 0.10 * 
Liver TAG (mg/g liver) 2.2 ± 0.12 1.2 ± 0.06 48 ± 0.67 # 29.4 ± 0.50 * 
Table 1. Analyses of body weight, serum enzymes and metabolites, liver weight and liver triglyceride (TAG) 722 
content in mice. CHOL: total cholesterol; LDL: low-density lipoprotein cholesterol; HDL: high-density 723 
lipoprotein cholesterol; BHB: β-hydroxybutyric acid; ALT: alanine aminotransferase; and AST: aspartate 724 
aminotransferase. Measures were performed in 28-week old mice, 11 weeks after injection of the AAV9s. Data 725 
are means ± SEM. n = 5–6. *P < 0.05 versus HFD-GFP, #P < 0.01 versus NCD-GFP. NCD: normal chow diet, 726 
HFD: high-fat diet.    727 
 728 
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 730 
 Lean Obese Pre-surgery 
Obese 
Post-
surgery 
P 
(lean vs. obese 
pre-surgery) 
P 
(obese pre- vs. 
post-surgery) 
N 15 15 15 - - 
Sex (male/female) 4/11 4/11 4/11 0.659 0.659 
Age (years) 42  3 45  3 46  3 0.470 <0.0001 
Height (m) 1.66  0.02 1.64  0.02 1.64  0.02 0.606 0.334 
Weight (kg) 63  3 117  6 79  5 <0.00001 <0.00001 
BMI (kg/m2) 22.7  0.8 43.0  1.2 29.1  1.0 <0.00001 <0.00001 
Body fat (%) 28.7  2.4 50.8  1.3 36.1  2.0 <0.00001 <0.00001 
Waist circumference (cm) 80  3 120  4 95  3 <0.00001 <0.00001 
Glucose (mg/dL) 84  2 104  3 90  8 <0.00001 <0.00001 
Glucose 2-h OGTT (mg/dL) 95  4 157  8 
- 
<0.00001 
- 
Insulin (U/mL) 5.8  0.9 19.2  2.0   6.9  1.0 <0.00001 <0.00001 
Insulin 2-h OGTT (U/mL) 44.9  7.0 163.8  24.4 - 0.002 - 
HOMA 1.2  0.2 5.0  0.6   1.6  0.2 <0.00001 <0.00001 
QUICKI 0.39  0.01 0.31  0.01 
  0.37  
0.01 
<0.00001 <0.00001 
Triacylglycerols (mg/dL) 78  8 155  17 83  9 <0.00001 0.002 
Total cholesterol (mg/dL) 192  6 222  9     165  10 0.009 0.623 
LDL-cholesterol (mg/dL) 109  6 136  8 102  6 0.007 0.041 
HDL-cholesterol (mg/dL) 68  4 51  5 54  3 0.014 0.050 
CRP (mg/L) 2.0  0.6 10.2  2.0   2.9  0.9 0.003 0.012 
Uric acid (mg/dL) 4.3  0.2 6.2  0.4   5.0  0.4 <0.00001 0.032 
Leptin (ng/mL) 11.0  2.2 48.6  6.3 12.7  3.1 <0.00001 <0.00001 
AST (IU/L) 13  1 18  2 15  1 0.047 0.057 
ALT (IU/L) 9  1 29  5 22  5 0.001 <0.00001 
Alkaline phosphatase (IU/L) 85  4 100  8 77  10 0.097 0.132 
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-GT (IU/L) 12  2 32  9 17  6 0.042 <0.00001 
TSH (U/mL) 1.7  0.3 3.2  1.3 - 0.396 - 
Daily alcohol intake (g) 2.1  1.1 0.9  0.7 - 0.405 - 
Antihypertensive therapy, n (%)  1 (6.7%) 6 (40.0%) 1 (6.7%) 0.060 0.019 
Antidiabetic therapy, n (%) 0 (0%) 0 (0%) 0 (0%) 1.000 1.000 
Lipid-lowering therapy, n (%) 0 (0%) 1 (6.7%) 0 (0%) 0.536 0.334 
Table 2. Clinical characteristics of the subjects included in the study. NG, normoglycemia; IGT, impaired 731 
glucose tolerance; T2D, type 2 diabetes; BMI, body mass index; HOMA, homeostasis model assessment; 732 
QUICKI, quantitative insulin sensitivity check index; AST, aspartate aminotransferase; ALT, alanine 733 
aminotransferase; -GT, -glutamyltransferase; CRP, high-sensitivity C-reactive protein; TSH, thyroid-734 
stimulating hormone. Bold values denote statistically significant P values. Differences between lean subjects 735 
and patients with obesity before surgery were analyzed by Student’s t test or χ2 test, where appropriate. The 736 
impact of weight loss in patients with obesity before and 6 months after Roux-en-Y gastric bypass (RYGB) was 737 
analyzed by paired two-tailed Student’s t test. n = 15. 738 
739 
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 740 
Pathological characteristics Obese NAFLD 
Steatosis   
     <5% 27% 
     5-33% 53% 
     34-66% 13% 
     >66% 7% 
Lobular inflammation   
     No foci 33% 
     <2 foci, per 200X field 13% 
     2-4 foci, per 200X field 47% 
     >4 foci, per 200X field 7% 
Portal inflammation  
     None to minimal 27% 
     Greater than minimal 73% 
Fibrosis stage  
     None 60% 
     Perisinusoidal or periportal/portal 13% 
     Perisinusoidal and portal/periportal 20% 
     Bridging fibrosis 7% 
     Cirrhosis 0% 
Hepatocyte balooning  
     None 60% 
     Few balloon cells 33% 
     Many prominent balloon cells 7% 
Mallory’s hyaline  
     None to rare 100% 
     Many 0% 
Glycogenated nuclei  
     None to rare 100% 
     Many 0% 
Anatomopathological diagnosis  
     NAFLD 60% 
     NASH 40% 
Table 3. Pathology analysis of liver biopsies obtained from patients with morbid obesity and NAFLD. 741 
742 
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Figure captions 743 
Figure 1. Expression of hCPT1AM increases FAO in hepatocytes and improves metabolic parameters 744 
and decreases hepatic steatosis in HFD-fed obese mice. (A) Experiment design and time course. (B) CPT1A 745 
activity in isolated mitochondria from NCD- and HFD-fed mice expressing either GFP or hCPT1AM. (C) 746 
Long-chaing acylcarnitines were measured in liver and serum samples from GFP- and hCPT1AM-expressing 747 
mice as an indirect indicator of CPT1A activity. (D) oleate oxidation to CO2 in isolated hepatocytes from NCD- 748 
and HFD-fed mice expressing either GFP or hCPT1AM. (E) Body weight (*P < 0.05, **P < 0.01, HFD-GFP 749 
versus HFD-hCPT1AM) of NCD- and HFD-fed mice after treatment with AAV9-GFP or AAV9-hCPT1AM. 750 
Fasting blood (F) glucose and (G) insulin levels NCD- and HFD-fed mice after treatment with AAV9-GFP or 751 
AAV9-hCPT1AM. (H) Glucose tolerance test of NCD- and HFD-fed mice after treatment with AAV9-GFP or 752 
AAV9-hCPT1AM. (I) Insulin signaling in isolated hepatocytes from NCD- and HFD-fed mice expressing 753 
either GFP or hCPT1AM, as indicated by Western blotting of insulin-induced Akt phosphorylation (pAkt, 754 
Ser473). Quantification of pAkt normalized by total Akt (N=4). A.U. = arbitrary units. N=5–6 (unless stated 755 
otherwise), *P < 0.05, **P < 0.01, ***P < 0.001. 756 
Figure 2. Expression of hCPT1AM decreases hepatic steatosis in HFD-fed obese mice. (A) Liver 757 
macroscopic appearance (left panel), and histology (haematoxylin and eosin staining, scale bar is 50 m) (right 758 
panel) in NCD- and HFD-fed mice after treatment with AAV9-GFP or AAV9-hCPT1AM. (B) Protein levels of 759 
HMGCS2, the rate-limiting enzyme of hepatic ketogenesis, and UCP2 in liver of NCD- and HFD-fed mice 760 
expressing either GFP or hCPT1AM, as indicated by Western blotting. Quantification is normalized by β-actin 761 
(N=3). (C) Liver temperature as indicated by infrared thermography and (D) liver ATP levels in NCD- and 762 
HFD-fed mice after treatment with AAV9-GFP or AAV9-hCPT1AM. (E) Mitochondrial respiratory capacity in 763 
isolated mitochondria from NCD- and HFD-fed mice expressing either GFP or hCPT1AM. A.U. = arbitrary 764 
units. N=5–6 (unless stated otherwise), *P < 0.05, **P < 0.01, ***P < 0.001. 765 
Figure 3. Expression of hCPT1AM in liver increases hepatic autophagy and modulates cholesterol 766 
metabolism in HFD-fed mice. (A) Levels of PLIN2 and PLIN5 in liver of NCD- and HFD-fed mice 767 
expressing either GFP or hCPT1AM, as indicated by Western blotting. Quantification is normalized by β-actin. 768 
(B) mRNA levels of Atg7 in the liver of NCD- and HFD-fed mice after treatment with AAV9-GFP or AAV9-769 
hCPT1AM. (C) Levels of LC3I/II and p62 in the liver of NCD- and HFD-fed mice expressing either GFP or 770 
hCPT1AM, as indicated by Western blotting. Quantification is normalized by β-actin. (N=3). (D) 771 
Quantification of net autophagy flux in isolated hepatocytes from NCD- and HFD-fed mice expressing either 772 
GFP or hCPT1AM, as indicated by Western blotting of CQ-induced LC3II accumulation. Quantification is 773 
normalised by -actin (N=2). (E) Levels of LDLr, VLDLr and LRP1 in the liver of NCD- and HFD-fed mice 774 
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expressing either GFP or hCPT1AM, as indicated by Western blotting. Quantification is normalised by β-actin 775 
(N=3). (F) mRNA levels of Mtp, Abca1, Abcg5 and Abcg8 in the liver of NCD- and HFD-fed mice after 776 
treatment with AAV9-GFP or AAV9-hCPT1AM. A.U. = arbitrary units. CQ = chloroquine. N = 5–6 (unless 777 
stated otherwise), *P < 0.05, **P < 0.01, **P < 0.001. 778 
Figure 4. Lipidomic analyses of NCD- and HFD-fed mice after treatment with AAV9-GFP or AAV9-779 
hCPT1AM. Lipidomic analyses of NCD- and HFD-fed mice after treatment with AAV9-GFP or AAV9-780 
hCPT1AM. Unsupervised clustering of 18 mice (in columns) based on the quantification of (A) 42 lipids (in 781 
rows) in liver samples and (B) 24 lipids (in rows) in serum samples that exhibited statistically significant 782 
differences among NCD-GFP and HFD-GFP groups (2-way ANOVA P<0.01 adjusted for multiple 783 
comparisons using FDR). The unsupervised clustering was performed using complete linkage on the Euclidean 784 
distance among samples. The heatmap colors represent the values scaled by the standard deviation of every 785 
lipid value across all samples and centered on the average of the NCD-GFP mice. Blue cells indicate values 786 
below the average value of the NCD-GFP mice, while red cells indicate values above that average, in z-scores. 787 
The lipid species highlighted in red exhibited statistically significant differences among HFD-GFP and HFD-788 
hCPT1AM groups. Concentration of Cer (C20:0) and TAG (C50:1) (expressed in pmol equivalent) in liver (C) 789 
and serum (D) samples from NCD- and HFD-fed mice expressing either GFP or hCPT1AM (n = 4–6, **P < 790 
0.01, ***P < 0.001, ****P < 0.0001). Cer: ceramide; SM: sphingomyelin; GlucCer: glucosylceramide; PC: 791 
phosphatidylcholine; PE: phosphatidylethanolamine; PS: phosphatidylserine; DAG: diacylglycerol; TAG: 792 
triacylglycerol. Lipid species are annotated using the “lipid subclass” and “C followed by the total fatty acyl 793 
chain length:total number of unsaturated bonds” and (e.g., PC (C32:2)). If the sphingoid base residue was 794 
dihydrosphingosine, the name contains a “dh” prefix. Plasmalogens and lysophospholipids are annotated as 795 
described above, except that a “p” or “L” prefix is included, respectively.  796 
Figure 5. Lipidomic analyses in humans.  797 
(A) Unsupervised clustering of 42 donors (in columns) based on the quantification of 26 lipids (in rows) that 798 
exhibited statistically significant differences among groups (ANOVA P<0.01 adjusted for multiple comparisons 799 
using FDR).  The unsupervised clustering was performed using complete linkage on the Euclidean distance 800 
among samples. The heatmap colors represents the values scaled by the standard deviation of every lipid values 801 
across all samples and centered on the average of the lean individuals. Blue cells indicate values below the 802 
average value of the lean individuals, while red cells indicate values above that average, in z-scores. (B) (Left) 803 
Principal component analysis (PCA) of 42 donors based on the quantification of 141 lipids. To account for the 804 
large numerical differences among lipidic molecules, values were scaled to have unit variance before the PCA 805 
analysis. In blue, lean individuals (L); in yellow, obese patients pre-surgery (O); in orange the same patients 806 
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post-surgery (OP). The vertical lines indicate the mean value on the first principal component (PC1, explaining 807 
around 27% of the total variance) for the three groups, using the same color code. (Right) Uniform manifold 808 
approximation and projection (UMAP) of the same data. Color code as in the figure on the left. (C) (Left) 809 
Changes in serum lipid content (ΔLC, in x-axis) and its correlation with changes in BMI (y-axis). Every dot 810 
represents a lipid. ΔLC is the average difference in lipid content between pre- and post-surgery, measured in 12 811 
patients with complete data. To account for large variability in the average value of different lipids, the t-812 
Statistic values rather than the mean difference values are shown in the graph. Negative ΔLC t-Statistic values 813 
indicate lipids whose average value decreased after surgery. Conversely, positive values indicate lipids that 814 
increased after surgery. Dot sizes are proportional to the FDR-adjusted P-value. In red, lipids with FDR-815 
adjusted P-value < 0.05. (Right) Same plot than on the left, but dot sizes are proportional to the FDR-adjusted 816 
P-value of the correlation test. In red, those with FDR-adjusted P-value < 0.05. (D) Concentration of TAG 817 
(C50:1) (expressed in pmol equivalent) in sera samples from lean controls and obese patients before and after 818 
bariatric surgery (N=15, ****P < 0.0001). (E) Partial correlations of changes in lipid content with changes in 819 
NAFLD-related parameters, after selecting lipids that exhibited at least one of the five partial correlations with 820 
a P-value < 0.05 (dot size is proportional to the magnitude of the correlation. In red, negative partial 821 
correlations. In blue positive partial correlations). (F) Schematic representation of how AAV9-hCPT1AM 822 
reverses obesity-induced hepatic steatosis and the lipidomic strategy followed to identify TAG (C50:1) as a 823 
possible circulating biomarker for NAFLD. Cer: ceramide; SM: sphingomyelin; HexCer: hexosylceramides; 824 
PC, phosphatidylcholine; LPC: lysophosphatidylcholine; PE: phosphatidylethanolamine; LPEA: 825 
lysophosphatidylethanolamine; PC O-: ether-linked phosphatidylcholine; DAG: diacylglycerol; TAG: 826 
triacylglycerol; CE: cholesterol ester. Lipid species are annotated using the “lipid subclass” and “C followed by 827 
the total fatty acyl chain length:total number of unsaturated bonds” and (e.g., PC (C32:2)). 828 
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Figure S1. (A) Schema of the AAV vectors. The cassette contains GFP or hCPT1AM transgene driven by 32 
specific EalbAATp promoter. (B) Glucose and insulin levels and (C) body weight in mice fed an HFD for 9 33 
weeks. n = 5–6, *P < 0.05. 34 
 35 
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 54 
 55 
Figure S2. (A) AAV infection efficiency in primary isolated hepatocytes from AAV9-GFP-infected mice under 56 
NCD or HFD. (B) hCPT1AM mRNA expression in liver. (C) Protein levels of CPT1A and (D) TIM44 in liver 57 
of NCD- and HFD-fed mice expressing either GFP or hCPT1AM, as indicated by Western blotting. (E) CPT1A 58 
protein levels in heart and skeletal muscle of NCD- and HFD-fed mice after treatment with AAV9-GFP or 59 
AAV9-hCPT1AM, as indicated by Western blotting (N=3). N=5–6 (unless stated otherwise), *P < 0.05, **P < 60 
0.01, ***P < 0.001. 61 
62 
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Figure S3. (A) Daily food intake measured in NCD- and HFD-fed mice after treatment with AAV9-GFP or 81 
AAV9-hCPT1AM. (B) Lipid levels in hepatocytes isolated from NCD- and HFD-fed mice expressing either 82 
GFP or hCPT1AM, as determined by oil red O staining. (C) Complex I (CI)-linked O2 consumption in isolated 83 
mitochondria from NCD- and HFD-fed mice expressing either GFP or hCPT1AM. (D) Levels of mitochondrial 84 
OXPHOS complexes CV-ATP5A, CIV-MTCO1, CII-SDHB and CI-NDUFB8 in liver of NCD- and HFD-fed 85 
mice after treatment with AAV9-GFP or AAV9-hCPT1AM, as indicated by Western blotting. Quantification is 86 
normalised by -actin (N=3). A.U. = arbitrary units. N=5–6 (unless stated otherwise), *P < 0.05, **P < 0.01, 87 
***P < 0.001. 88 
89 
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Figure S4. (A) mRNA levels of Mfn1, Mfn2, and Opa1 in the liver of NCD- and HFD-fed mice after treatment 107 
with AAV9-GFP or AAV9-hCPT1AM. (B) mRNA levels of Atgl, Hsl, and Mgl in the liver of NCD- and HFD-108 
fed mice after treatment with AAV9-GFP or AAV9-hCPT1AM. (C) Phosphorylated HSL (pHSL) (Ser563, 109 
Ser565, Ser660), HSL and ATGL protein levels in liver of NCD- and HFD-fed mice expressing either GFP or 110 
hCPT1AM, as indicated by Western blotting (N=3). (D) Hmgcr and Srebp2 in the liver of NCD- and HFD-fed 111 
mice after treatment with AAV9-GFP or AAV9-hCPT1AM. A.U. = arbitrary units. N = 5–6 (unless stated 112 
otherwise), *P < 0.05. 113 
 114 
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Supplementary Tables 116 
 
Mice 
ID 
Steatosis 
(0-2) 
Ballooning             
(0-2) 
Lobular 
inflammation 
(0-3) 
NAFLD 
activity 
score (0 
to 8) 
NAS: 0-2 
(non-
NASH), 3-4 
(borderline), 
5-8 (NASH) 
Bedossa et 
al, 
Hepatology, 
2012 
NCD-GFP 
1 1 0 0 1 non-NASH NAFLD 
2 0 0 0 0 non-NASH No NAFLD 
3 0 0 0 0 non-NASH No NAFLD 
4 0 0 0 0 non-NASH No NAFLD 
5 1 0 0 1 non-NASH NAFLD 
6 0 0 0 0 non-NASH No NAFLD 
NCD-
hCPT1AM 
1 0 0 0 0 non-NASH No NAFLD 
2 0 0 1 1 non-NASH No NAFLD 
3 1 0 0 1 non-NASH NAFLD 
4 0 0 1 1 non-NASH No NAFLD 
5 1 0 1 2 non-NASH NAFLD 
HFD-GFP 
1 2 0 1 3 Borderline NAFLD 
2 2 0 1 3 Borderline NAFLD 
3 2 1 2 5 NASH NAFLD 
4 2 0 1 3 Borderline NAFLD 
5 2 0 1 3 Borderline NAFLD 
6 2 1 1 4 Borderline NAFLD 
HFD-
hCPT1AM 
1 1 0 1 2 non-NASH NAFLD 
2 2 0 0 2 non-NASH NAFLD 
3 1 0 1 2 non-NASH NAFLD 
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4 2 0 0 2 non-NASH NAFLD 
5 2 0 0 2 non-NASH NAFLD 
6 1 0 1 2 non-NASH NAFLD 
 117 
 118 
Table S1. Histopathological analysis of liver samples. The samples were assessed on H&E stained slides and 119 
scored according to the NAFLD activity score (NAS), as described in the Material and Methods. Steatosis was 120 
scored 0 when it was absent, 1 when a minimal amount of steatosis was present, and 2 when moderate-to-121 
marked steatosis was observed in the tissue. Ballooning was graded as either 0 when it was absent or 1 when 122 
there were clusters of hepatocytes with a rounded shape, and pale cytoplasm was usually reticulated. Lobular 123 
inflammation was defined as a focus of two or more inflammatory cells within the lobule. Foci were counted at 124 
200X magnification (0: none; 1: 2 foci per 200X; 2: >2foci per 200X).  125 
